Studying the Clinical Course of Risankizumab

Studying the Clinical Course of Risankizumab

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description
Risankizumab is a medication used for the treatment of Crohn's Disease in adults and children to limit symptoms of the disease. However, as children differ more than adults in their age/weight range and the way that drugs move around their body, more information is needed to understand the factors that might affect the response to the drug in children. 

Eligibility and criteria
IRB Number:
24-021971
Eligible age range:
1 months - 17 years
Clinical trial phase:
N/A
Official title:
Risankizumab in Children with Crohn's Disease: A Multi-Center PORTO Group Prospective Study

What to expect
Participation will last for approximately 3 years and involve 8 study visits. Each visit will include a study questionnaire and a physical examination, if one was not completed at a recent office visit. The study team will also look through participants' medical records for demographic, medication, and disease activity data.

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.